肝动脉灌注化疗在肝细胞癌治疗中研究进展
Research progress of hepatic arterial Infusion chemotherapy in the treatment of hepatocellular carcinoma
张炜浩 1高炜 1司同国 1邢文阁 1于海鹏 1陈璐2
作者信息
- 1. 天津医科大学肿瘤医院 国家肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心 天津市消化系统肿瘤重点实验室药物成药性评价与系统转化重点实验室介入治疗科,天津 300060
- 2. 天津医科大学肿瘤医院 国家肿瘤临床医学研究中心天津市恶性肿瘤临床医学研究中心 天津市消化系统肿瘤重点实验室药物成药性评价与系统转化重点实验室肝胆肿瘤科,天津 300060
- 折叠
摘要
以靶向、免疫治疗为代表的系统治疗是晚期肝细胞癌的标准治疗,但总体有效率并不高.肝动脉灌注化疗(HAIC)能够有效控制肝内肿瘤,且微创、安全性好.系统治疗联合HAIC能有效提高客观缓解率和疾病控制率,改善生活质量.目前文献报道,HAIC在外科术前降期、术后辅助和综合治疗中均有积极应用.但如何在病人初诊时筛选出优势人群,根据病人的病情特点做到个体化用药,仍需深入探讨.
Abstract
Hepatocellular carcinoma(HCC)is one of the most common malignant tumors,which seriously threatens the health and quality of life of Chinese people.Systematic therapy represented by targeted and immunotherapy is the standard treatment for advanced HCC,but the overall effective rate is not high.Hepatic arterial infusion chemotherapy(HAIC)can effectively control intrahepatic tumors,with the advantages of minimally invasiveness and good safety.Systemic therapy combined with HAIC can effectively improve the objective remission rate and disease control rate,and improve the quality of life.Currently,there are reports on the positive application of HAIC in the downgrading before surgery,adjuvant treatment after surgery,and comprehensive treatment.However,how to screen out the advantageous population at the initial diagnosis of patients and achieve individualized medication according to the characteristics of patients'condition still needs to be further explored.
关键词
肝细胞癌/肝动脉灌注化疗/分子靶向治疗/免疫治疗Key words
hepatocellular carcinoma/hepatic artery infusion chemotherapy/molecular targeted therapy/immunotherapy引用本文复制引用
基金项目
天津市教委科研计划项目(2023KJ090)
出版年
2024
国家科技期刊平台
NSTL
万方数据